Loading data for HELP — first visit, this takes a few seconds.

알림

Cybin D/B/A Helus Pharma (HELP)

NasdaqGM: HELP · 실시간 가격 · USD

13.98

+0.96 (7.37%)

종가 기준: Aug 26, 2026, 3:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

7.37% (1D)

매수호가	6.79
시가총액	995.81M
매출 (ttm)	n/a
순이익 (ttm)	-171.2M
	0.56
	-4.06
	n/a
	-7.43
P/B (ttm)	253.76
P/S (ttm)	n/a
실적 발표일	Nov 12, 2026

매도호가	11.87
거래량	2,997,868
평균 거래량 (20일)	1,519,825
시가	13.16
전일 종가	13.02
일중 범위	13.04 - 14.35
52주 범위	3.76 - 14.35
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

HELP 소개

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company'...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 13, 2019

직원 수 100

상장 거래소 NasdaqGM

티커 HELP

웹사이트 https://www.helus.com

전체 기업 정보

재무 실적

2026년 Cybin D/B/A Helus Pharma의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -148M로, 81.35% 증가했습니다.

재무제표

어닝 서프라이즈

Cybin D/B/A Helus Pharma가 Aug 14, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -1.26 예상치 상회 0.12, 및 -29.90% 전년 대비 감소.

다음 실적 발표

Cybin D/B/A Helus Pharma의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1일 전 · Simply Wall St.

Cybin (HELP) Gets A Fresh Look On Trial Progress And CEO Change

Why Cybin Stock Is Back on Investors’ Radar Cybin (HELP) has attracted fresh attention after progress in its psychedelic medicine pipeline, including HLP003 advancing into a Phase 3 trial for major de...

4일 전 · Simply Wall St.

Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions

Cybin’s fair value estimate has moved from US$37.57 to US$41.62 per share, an adjustment of about 11% in the latest analyst model. Recent sector research on psychedelic neuropsychiatry stocks, along w...

6일 전 · Simply Wall St.

3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now

Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.

1주 전 · MarketBeat

Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adj...

2주 전 · Simply Wall St.

Cybin (HELP) Names New CEO, Is The Stock Still Cheap?

Cybin (HELP) is in focus after Helus Pharma appointed Michael Halstead as Chief Executive Officer on 3 August 2026. He brings 25 years of pharmaceutical leadership across product launches, capital mar...

2 페이지 중 1

Cybin D/B/A Helus Pharma (HELP)